• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

主要肾脏疾病患者开始肾脏替代治疗的趋势的国际比较。

International comparison of trends in patients commencing renal replacement therapy by primary renal disease.

机构信息

ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.

Renal Registry Valencian Region, Generalitat Valencian, Spain.

出版信息

Nephrology (Carlton). 2019 Oct;24(10):1064-1076. doi: 10.1111/nep.13531. Epub 2019 Apr 29.

DOI:10.1111/nep.13531
PMID:30456883
Abstract

AIM

To examine international time trends in the incidence of renal replacement therapy (RRT) for end-stage renal disease (ESRD) by primary renal disease (PRD).

METHODS

Renal registries reporting on patients starting RRT per million population for ESRD by PRD from 2005 to 2014, were identified by internet search and literature review. The average annual percentage change (AAPC) with a 95% confidence interval (CI) of the time trends was computed using Joinpoint regression.

RESULTS

There was a significant decrease in the incidence of RRT for ESRD due to diabetes mellitus (DM) in Europe (AAPC = -0.9; 95%CI -1.3; -0.5) and to hypertension/renal vascular disease (HT/RVD) in Australia (AAPC = -1.8; 95%CI -3.3; -0.3), Canada (AAPC = -2.9; 95%CI -4.4; -1.5) and Europe (AAPC = -1.1; 95%CI -2.1; -0.0). A decrease or stabilization was observed for glomerulonephritis in all regions and for autosomal dominant polycystic kidney disease (ADPKD) in all regions except for Malaysia and the Republic of Korea. An increase of 5.2-16.3% was observed for DM, HT/RVD and ADPKD in Malaysia and the Republic of Korea.

CONCLUSION

Large international differences exist in the trends in incidence of RRT by primary renal disease. Mapping of these international trends is the first step in defining the causes and successful preventative measures of CKD.

摘要

目的

通过主要肾脏疾病(PRD)检查终末期肾病(ESRD)接受肾脏替代治疗(RRT)的国际时间趋势。

方法

通过互联网搜索和文献回顾,确定了 2005 年至 2014 年期间按 PRD 报告每百万人口 ESRD 接受 RRT 的患者的肾脏登记处。使用 Joinpoint 回归计算时间趋势的平均年百分比变化(AAPC)及其 95%置信区间(CI)。

结果

在欧洲,由于糖尿病(DM)导致的 ESRD 接受 RRT 的发生率呈显著下降(AAPC=-0.9;95%CI-1.3;-0.5),在澳大利亚,由于高血压/肾血管疾病(HT/RVD)导致的发生率呈显著下降(AAPC=-1.8;95%CI-3.3;-0.3),在加拿大和欧洲,由于 HT/RVD 导致的发生率呈显著下降(AAPC=-2.9;95%CI-4.4;-1.5)和欧洲(AAPC=-1.1;95%CI-2.1;-0.0)。所有地区的肾小球肾炎以及除马来西亚和韩国以外的所有地区的常染色体显性多囊肾病(ADPKD)的发生率均下降或稳定。在马来西亚和韩国,DM、HT/RVD 和 ADPKD 的发生率分别增加了 5.2%-16.3%。

结论

不同国家和地区之间 RRT 发生率的趋势存在较大差异。绘制这些国际趋势图是确定 CKD 病因和成功预防措施的第一步。

相似文献

1
International comparison of trends in patients commencing renal replacement therapy by primary renal disease.主要肾脏疾病患者开始肾脏替代治疗的趋势的国际比较。
Nephrology (Carlton). 2019 Oct;24(10):1064-1076. doi: 10.1111/nep.13531. Epub 2019 Apr 29.
2
ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.2001 - 2010年美国常染色体显性多囊肾病导致的终末期肾病
Am J Kidney Dis. 2014 Oct;64(4):592-9. doi: 10.1053/j.ajkd.2014.05.020. Epub 2014 Aug 16.
3
Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.英格兰和威尔士常染色体显性多囊肾病及终末期肾衰竭患者的流行病学情况。
Nephrol Dial Transplant. 2014 Oct;29(10):1910-8. doi: 10.1093/ndt/gfu087. Epub 2014 Apr 15.
4
An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.欧洲肾脏替代治疗的最新进展:1997 年至 2006 年 ERA-EDTA 登记数据。
Nephrol Dial Transplant. 2009 Dec;24(12):3557-66. doi: 10.1093/ndt/gfp519. Epub 2009 Oct 9.
5
Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020.2006 - 2020年日本按原发性肾脏疾病类型划分的肾脏替代治疗发生率趋势
Nephrology (Carlton). 2023 Feb;28(2):119-129. doi: 10.1111/nep.14134. Epub 2022 Dec 8.
6
Association between attributed cause of end-stage renal disease and risk of death in Brazilian patients receiving renal replacement therapy.巴西接受肾脏替代治疗患者的终末期肾病归因病因与死亡风险之间的关联。
Ren Fail. 2005;27(6):651-6. doi: 10.1080/08860220500234832.
7
Increases in renal replacement therapy in Australia and New Zealand: understanding trends in diabetic nephropathy.澳大利亚和新西兰肾脏替代治疗的增加:了解糖尿病肾病的趋势。
Nephrology (Carlton). 2012 Jan;17(1):76-84. doi: 10.1111/j.1440-1797.2011.01512.x.
8
The gap between estimated incidence of end-stage renal disease and use of therapy.估算的终末期肾病发病率与治疗使用率之间的差距。
PLoS One. 2013 Aug 30;8(8):e72860. doi: 10.1371/journal.pone.0072860. eCollection 2013.
9
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.欧洲接受肾脏替代治疗的系统性硬化症(硬皮病)患者的特征和结局:来自 ERA-EDTA 登记处的结果。
Am J Kidney Dis. 2019 Feb;73(2):184-193. doi: 10.1053/j.ajkd.2018.05.016. Epub 2018 Aug 16.
10
Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause.1983 - 2000年日本终末期肾病发病率趋势:按性别和病因划分的年龄调整率和特定年龄率。
Nephrol Dial Transplant. 2004 Aug;19(8):2044-52. doi: 10.1093/ndt/gfh317. Epub 2004 Jun 1.

引用本文的文献

1
What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.在管理 2 型糖尿病患者时不应忽视的问题:肾脏病学和肝脏病学视角。
Int J Mol Sci. 2024 Jul 15;25(14):7728. doi: 10.3390/ijms25147728.
2
Simultaneous Pancreatic and Kidney Transplant in Adult with Autosomal Dominant Polycystic Kidney Disease and Type I Diabetes Mellitus: Post Surgical Events and Genetic Review.成人常染色体显性遗传性多囊肾病合并Ⅰ型糖尿病患者的胰肾联合移植:术后情况及遗传学综述
Oman Med J. 2024 May 30;39(3):e636. doi: 10.5001/omj.2024.18. eCollection 2024 May.
3
Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry.
原发性肾小球疾病导致的终末期肾病在欧洲进行肾脏替代治疗的发生率和结局:来自 ERA 登记处的研究结果。
Nephrol Dial Transplant. 2024 Aug 30;39(9):1449-1460. doi: 10.1093/ndt/gfae034.
4
Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?SGLT2抑制剂在递增式血液透析患者中的疗效与安全性:最大化残余肾功能,SGLT2抑制剂是否能发挥作用?
Biomedicines. 2023 Jul 6;11(7):1908. doi: 10.3390/biomedicines11071908.
5
Effect of frailty, physical performance, and chronic kidney disease on mortality in older patients with diabetes : a retrospective longitudinal cohort study.衰弱、身体机能及慢性肾脏病对老年糖尿病患者死亡率的影响:一项回顾性纵向队列研究
Diabetol Metab Syndr. 2023 Jan 17;15(1):7. doi: 10.1186/s13098-022-00972-0.
6
Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis.胰高血糖素样肽-1受体激动剂司美格鲁肽在实际应用中的疗效与安全性:维持性递增血液透析患者的病例系列研究
Case Rep Nephrol Dial. 2022 Nov 22;12(3):238-247. doi: 10.1159/000527919. eCollection 2022 Sep-Dec.
7
Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study.在过去十年中,在欧洲接受肾脏替代治疗的患者数量不断增加,整体生存率也得到了提高:一项 ERA 登记研究。
Nephrol Dial Transplant. 2023 Mar 31;38(4):1027-1040. doi: 10.1093/ndt/gfac165.
8
Optimizing the timing of nephrology referral for patients with diabetic kidney disease.优化糖尿病肾病患者肾病转诊的时机。
Clin Kidney J. 2020 Aug 5;14(1):5-8. doi: 10.1093/ckj/sfaa125. eCollection 2021 Jan.
9
Evidence-based medicine-When observational studies are better than randomized controlled trials.循证医学——当观察性研究优于随机对照试验时。
Nephrology (Carlton). 2020 Oct;25(10):737-743. doi: 10.1111/nep.13742. Epub 2020 Jul 2.
10
The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps.全球糖尿病肾病负担:时间趋势和性别差距。
Curr Diab Rep. 2019 Mar 2;19(4):18. doi: 10.1007/s11892-019-1133-6.